StockData
Acurx Pharmaceuticals, Inc. logo

Acurx Pharmaceuticals, Inc. (ACXP) stock

ACXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$1.00+0.01 (+1.01%)

Close on Nov 18, 2026Market cap $5.27MP/E –Yield –

Acurx Pharmaceuticals operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Acurx Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was -$6.18M. For fiscal 2025 it was -$6.79M. The highest annual figure on record is -$3.35M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$6.79M–
FY2024Dec 31, 2024-$10.38M–
FY2023Dec 31, 2023-$9.80M–
FY2022Dec 31, 2022-$7.54M–
FY2021Dec 31, 2021-$5.01M–
FY2020Dec 31, 2020-$3.35M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$1.71M–
Q1 FY2026Mar 31, 2026-$1.41M–
Q4 FY2025Dec 31, 2025-$1.18M–
Q3 FY2025Sep 30, 2025-$1.88M–
Q2 FY2025Jun 30, 2025-$1.67M–
Q1 FY2025Mar 31, 2025-$2.05M–
Q4 FY2024Dec 31, 2024-$2.25M–
Q3 FY2024Sep 30, 2024-$2.19M–
Q2 FY2024Jun 30, 2024-$2.88M–
Q1 FY2024Mar 31, 2024-$3.06M–
Q4 FY2023Dec 31, 2023-$4.20M–
Q3 FY2023Sep 30, 2023-$2.09M–
Q2 FY2023Jun 30, 2023-$1.58M–
Q1 FY2023Mar 31, 2023-$1.93M–
Q4 FY2022Dec 31, 2022-$1.50M–
Q3 FY2022Sep 30, 2022-$2.18M–
Q2 FY2022Jun 30, 2022-$1.99M–
Q1 FY2022Mar 31, 2022-$1.88M–
Q4 FY2021Dec 31, 2021-$1.50M–
Q3 FY2021Sep 30, 2021-$2.64M–
Q2 FY2021Jun 30, 2021-$329.81K–
Q1 FY2021Mar 31, 2021-$547.14K–
Q4 FY2020Dec 31, 2020-$959.75K–
Q3 FY2020Sep 30, 2020-$758.76K–

More Acurx Pharmaceuticals figures

See a number that looks wrong?